Skip to main content
Erschienen in: Acta Diabetologica 2/2015

01.04.2015 | Original Article

Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations

verfasst von: Augusto Boido, Valerio Ceriani, Antonio E. Pontiroli

Erschienen in: Acta Diabetologica | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Aims

Glucagon is used as an emergency drug in hypoglycemia, mainly when the patient is unconscious. A few studies report on ineffectiveness of glucagon in relieving hypoglycemia. The present systematic review and meta-analysis evaluate the effectiveness of glucagon alone and in comparison with dextrose and the effectiveness of intranasal glucagon in comparison with injected glucagon.

Methods

Studies were grouped into three groups: (1) reports on glucagon ineffectiveness; (2) comparison of glucagon and dextrose; (3) comparison of intranasal glucagon and injected glucagon. In groups 2 and 3, only controlled studies were included in the analysis, whether randomized or non-randomized studies. Appropriate methodology (PRISMA statement) was adhered to, and publication bias was formally assessed. Sixteen studies, published in any language as full papers, were analysed to identify predictors of ineffectiveness, and they were included in a meta-analysis (random effects model) to study the effect of different strategies. Intervention effect (number of failures) was expressed as odds ratio (OR), with 95 % confidence intervals.

Results

Failure rate ranged from 0.0 to 2.31 %, to 7.6 %, to 14.4 %, and to 59 %. Comparing glucagon and dextrose, the OR was 0.53 (0.20–1.42); comparing intranasal and intramuscular glucagon, the OR was 1.40 (0.18–10.93). Heterogeneity was low and not statistically significant. Publication bias was absent.

Conclusions

These data indicate that ineffectiveness of glucagon is unfrequent, not different from dextrose; in addition, intranasal and injected glucagon are similarly effective. In the case of failure, a second dose can be administered.
Literatur
1.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
2.
Zurück zum Zitat The United Kingdom Prospective Diabetes Study Research Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853CrossRef The United Kingdom Prospective Diabetes Study Research Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837–853CrossRef
3.
Zurück zum Zitat Lithovius R, Harjutsalo V, Forsblom C, Saraheimo M, Groop P-H (2014) The consequences of failure to achieve targets of guidelines for prevention and treatment of diabetic complications in patients with type 1 diabetes. Acta Diabetol. doi:10.1007/s00592-014-0595-x Lithovius R, Harjutsalo V, Forsblom C, Saraheimo M, Groop P-H (2014) The consequences of failure to achieve targets of guidelines for prevention and treatment of diabetic complications in patients with type 1 diabetes. Acta Diabetol. doi:10.​1007/​s00592-014-0595-x
4.
Zurück zum Zitat Allicar MP, Mégas F, Houzard S, Baroux A, Le Thai F, Augendre-Ferrante B (2000) Frequency and costs of hospital stays for hypoglycemia in France in 1995. Presse Med 29:657–661PubMed Allicar MP, Mégas F, Houzard S, Baroux A, Le Thai F, Augendre-Ferrante B (2000) Frequency and costs of hospital stays for hypoglycemia in France in 1995. Presse Med 29:657–661PubMed
5.
Zurück zum Zitat Cryer PE (2002) Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45:937–948CrossRefPubMed Cryer PE (2002) Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45:937–948CrossRefPubMed
6.
Zurück zum Zitat Centers for Disease Control and Prevention (CDC) (2011) National diabetes fact sheet: national estimates, general information on diabetes, prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA Centers for Disease Control and Prevention (CDC) (2011) National diabetes fact sheet: national estimates, general information on diabetes, prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA
7.
Zurück zum Zitat MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10:238–245CrossRefPubMed MacLeod KM, Hepburn DA, Frier BM (1993) Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10:238–245CrossRefPubMed
8.
9.
Zurück zum Zitat UK Hypoglycemia Study Group (2007) Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50:1140–1147CrossRef UK Hypoglycemia Study Group (2007) Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 50:1140–1147CrossRef
10.
Zurück zum Zitat Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD, DARTS/MEMO Collaboration (2003) Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26:1176–1180CrossRefPubMed Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD, DARTS/MEMO Collaboration (2003) Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care 26:1176–1180CrossRefPubMed
11.
Zurück zum Zitat Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, Budnitz DS (2014) National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 174:678–686CrossRefPubMed Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, Budnitz DS (2014) National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 174:678–686CrossRefPubMed
12.
Zurück zum Zitat Merlotti C, Morabito A, Ceriani V, Pontiroli AE (2014) Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis. Acta Diabetol 51:853–863CrossRefPubMed Merlotti C, Morabito A, Ceriani V, Pontiroli AE (2014) Prevention of type 2 diabetes in obese at-risk subjects: a systematic review and meta-analysis. Acta Diabetol 51:853–863CrossRefPubMed
13.
Zurück zum Zitat Cryer PE (1997) Hypoglycemia. Pathophysiology, diagnosis and treatment. Oxford Univ. Press, New York Cryer PE (1997) Hypoglycemia. Pathophysiology, diagnosis and treatment. Oxford Univ. Press, New York
14.
Zurück zum Zitat Gossain VV, Carella MJ, Rovner DR (1994) Management of diabetes in the elderly: a clinical perspective. J Assoc Acad Minor Phys 5:22–31PubMed Gossain VV, Carella MJ, Rovner DR (1994) Management of diabetes in the elderly: a clinical perspective. J Assoc Acad Minor Phys 5:22–31PubMed
15.
Zurück zum Zitat Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, DE Grobbee, Kengne AP, Marre M, Heller S, ADVANCE Collaborative Group (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418CrossRefPubMed Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, DE Grobbee, Kengne AP, Marre M, Heller S, ADVANCE Collaborative Group (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418CrossRefPubMed
16.
Zurück zum Zitat Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM (2001) Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161:1653–1659CrossRefPubMed Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM (2001) Hypoglycemia in patients with type 2 diabetes mellitus. Arch Intern Med 161:1653–1659CrossRefPubMed
17.
Zurück zum Zitat Socransky SJ, Pirrallo RG, Rubin JM (1998) Out-of-hospital treatment of hypoglycemia: refusal of transport and patient outcome. Acad Emerg Med 5:1080–1085CrossRefPubMed Socransky SJ, Pirrallo RG, Rubin JM (1998) Out-of-hospital treatment of hypoglycemia: refusal of transport and patient outcome. Acad Emerg Med 5:1080–1085CrossRefPubMed
18.
Zurück zum Zitat Lobmann R, Smid HG, Pottag G, Wagner K, Heinze HJ, Lehnert H (2000) Impairment and recovery of elementary cognitive function induced by hypoglycemia in type-1 diabetic patients and healthy controls. J Clin Endocrinol Metab 85:2758–2766CrossRefPubMed Lobmann R, Smid HG, Pottag G, Wagner K, Heinze HJ, Lehnert H (2000) Impairment and recovery of elementary cognitive function induced by hypoglycemia in type-1 diabetic patients and healthy controls. J Clin Endocrinol Metab 85:2758–2766CrossRefPubMed
19.
Zurück zum Zitat DIAMOND Project Group (2006) Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 23:857–866CrossRef DIAMOND Project Group (2006) Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabet Med 23:857–866CrossRef
20.
Zurück zum Zitat Köster I, Huppertz E, Hauner H, Schubert I (2011) Direct costs of diabetes mellitus in Germany—CoDiM 2000–2007. Exp Clin Endocrinol Diabetes 119:377–385CrossRefPubMed Köster I, Huppertz E, Hauner H, Schubert I (2011) Direct costs of diabetes mellitus in Germany—CoDiM 2000–2007. Exp Clin Endocrinol Diabetes 119:377–385CrossRefPubMed
21.
Zurück zum Zitat Holstein A, Patzer OM, Machalke K, Holstein JD, Stumvoll M, Kovacs P (2012) Substantial increase in incidence of severe hypoglycemia between 1997–2000 and 2007–2010: a German longitudinal population-based study. Diabetes Care 35:972–975CrossRefPubMedCentralPubMed Holstein A, Patzer OM, Machalke K, Holstein JD, Stumvoll M, Kovacs P (2012) Substantial increase in incidence of severe hypoglycemia between 1997–2000 and 2007–2010: a German longitudinal population-based study. Diabetes Care 35:972–975CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat American Diabetes Association (2013) Standards of medical care in diabetes–diabetes—2013. Diabetes Care 36(Suppl 1):S11–S66CrossRefPubMedCentral American Diabetes Association (2013) Standards of medical care in diabetes–diabetes—2013. Diabetes Care 36(Suppl 1):S11–S66CrossRefPubMedCentral
23.
Zurück zum Zitat Zammitt NN, Frier BM (2005) Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28:2948–2961CrossRefPubMed Zammitt NN, Frier BM (2005) Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28:2948–2961CrossRefPubMed
24.
26.
Zurück zum Zitat Barret KE, Barman SM (2010) Endocrine functions of the pancreas and regulation of carbohydrate metabolism. Ganong’s Review of Medical Physiology, 23rd edn. McGraw-Hill, New York, pp 315–336 Barret KE, Barman SM (2010) Endocrine functions of the pancreas and regulation of carbohydrate metabolism. Ganong’s Review of Medical Physiology, 23rd edn. McGraw-Hill, New York, pp 315–336
27.
Zurück zum Zitat Holste LC, Connolly CC, Moore MC, Neal DW, Cherrington AD (1997) Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol 273:488–496 Holste LC, Connolly CC, Moore MC, Neal DW, Cherrington AD (1997) Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol 273:488–496
28.
Zurück zum Zitat Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD (2011) Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 13(Suppl 1):118–125CrossRefPubMed Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD (2011) Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 13(Suppl 1):118–125CrossRefPubMed
29.
Zurück zum Zitat Elrick H, Witten TA, Arai Y (1958) Glucagon treatment of insulin reactions. N Engl J Med 258:476–480CrossRefPubMed Elrick H, Witten TA, Arai Y (1958) Glucagon treatment of insulin reactions. N Engl J Med 258:476–480CrossRefPubMed
30.
Zurück zum Zitat Vukmir RB, Paris PM, Yealy DM (1991) Glucagon: pre-hospital therapy for hypoglycemia. Ann Emerg Med 20:375–379CrossRefPubMed Vukmir RB, Paris PM, Yealy DM (1991) Glucagon: pre-hospital therapy for hypoglycemia. Ann Emerg Med 20:375–379CrossRefPubMed
31.
Zurück zum Zitat Mühlhauser I, Koch J, Berger M (1985) Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care 8:39–42CrossRefPubMed Mühlhauser I, Koch J, Berger M (1985) Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscular, subcutaneous, and intravenous administration. Diabetes Care 8:39–42CrossRefPubMed
32.
Zurück zum Zitat Namba M, Hanafusa T, Kono N, Tarui S (1993) Clinical evaluation of biosynthetic glucagon treatment for recovery from hypoglycemia developed in diabetic patients. The GL-G Hypoglycemia Study Group. Diabetes Res Clin Pract 19:133–138CrossRefPubMed Namba M, Hanafusa T, Kono N, Tarui S (1993) Clinical evaluation of biosynthetic glucagon treatment for recovery from hypoglycemia developed in diabetic patients. The GL-G Hypoglycemia Study Group. Diabetes Res Clin Pract 19:133–138CrossRefPubMed
33.
Zurück zum Zitat Shipp JC, Delcher HK, Munroe JF (1964) Treatment of insulin hypoglycemia in diabetic campers; a comparison of glucagon (1 and 2 mg.) and glucose. Diabetes 13:645–648CrossRefPubMed Shipp JC, Delcher HK, Munroe JF (1964) Treatment of insulin hypoglycemia in diabetic campers; a comparison of glucagon (1 and 2 mg.) and glucose. Diabetes 13:645–648CrossRefPubMed
34.
Zurück zum Zitat Gibbs GE, Ebers DW, Meckel BR (1958) Use of glucagon to terminate insulin reactions in diabetic children. Nebr State Med J 43:56–57PubMed Gibbs GE, Ebers DW, Meckel BR (1958) Use of glucagon to terminate insulin reactions in diabetic children. Nebr State Med J 43:56–57PubMed
35.
Zurück zum Zitat Cornblath M, Levin EY, Marquetti E (1958) Studies of carbohydrate metabolism in the newborn. II. The effect of glucagon on the concentration of sugar in capillary blood of the newborn infant. Pediatrics 21:885–892PubMed Cornblath M, Levin EY, Marquetti E (1958) Studies of carbohydrate metabolism in the newborn. II. The effect of glucagon on the concentration of sugar in capillary blood of the newborn infant. Pediatrics 21:885–892PubMed
36.
37.
Zurück zum Zitat Aman J, Wranne L (1988) Hypoglycaemia in childhood diabetes. II. Effect of subcutaneous or intramuscular injection of different doses of glucagon. Acta Paediatr Scand. 77:548–553CrossRefPubMed Aman J, Wranne L (1988) Hypoglycaemia in childhood diabetes. II. Effect of subcutaneous or intramuscular injection of different doses of glucagon. Acta Paediatr Scand. 77:548–553CrossRefPubMed
38.
Zurück zum Zitat Haymond MW, Schreiner B (2001) Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 24:643–645CrossRefPubMed Haymond MW, Schreiner B (2001) Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 24:643–645CrossRefPubMed
39.
Zurück zum Zitat Miralles RE, Lodha A, Perlman M, Moore AM (2002) Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia. Arch Pediatr Adolesc Med 156:999–1004CrossRefPubMed Miralles RE, Lodha A, Perlman M, Moore AM (2002) Experience with intravenous glucagon infusions as a treatment for resistant neonatal hypoglycemia. Arch Pediatr Adolesc Med 156:999–1004CrossRefPubMed
40.
Zurück zum Zitat Mohnike K, Blankenstein O, Pfuetzner A, Pötzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM (2008) Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 70:59–64CrossRefPubMed Mohnike K, Blankenstein O, Pfuetzner A, Pötzsch S, Schober E, Steiner S, Hardy OT, Grimberg A, van Waarde WM (2008) Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res 70:59–64CrossRefPubMed
41.
Zurück zum Zitat Pontiroli AE, Alberetto M, Pozza G (1983) Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br Med J (Clin Res Ed) 287:462–463CrossRef Pontiroli AE, Alberetto M, Pozza G (1983) Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br Med J (Clin Res Ed) 287:462–463CrossRef
42.
Zurück zum Zitat Pontiroli AE, Calderara A, Pajetta E, Alberetto M, Pozza G (1989) Intranasal glucagon as remedy for hypoglycemia. Studies in healthy subjects and type I diabetic patients. Diabetes Care 12:604–608CrossRefPubMed Pontiroli AE, Calderara A, Pajetta E, Alberetto M, Pozza G (1989) Intranasal glucagon as remedy for hypoglycemia. Studies in healthy subjects and type I diabetic patients. Diabetes Care 12:604–608CrossRefPubMed
43.
Zurück zum Zitat Freychet L, Rizkalla SW, Desplanque N, Basdevant A, Zirinis P, Tchobroutsky G, Slama G (1988) Effect of intranasal glucagon on blood glucose levels in healthy subjects and hypoglycaemic patients with insulin-dependent diabetes. Lancet. 1:1364–1366CrossRefPubMed Freychet L, Rizkalla SW, Desplanque N, Basdevant A, Zirinis P, Tchobroutsky G, Slama G (1988) Effect of intranasal glucagon on blood glucose levels in healthy subjects and hypoglycaemic patients with insulin-dependent diabetes. Lancet. 1:1364–1366CrossRefPubMed
44.
Zurück zum Zitat Rosenfalck AM, Bendtson I, Jorgensen S, Binder C (1992) Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin-dependent) diabetic patients. Diabetes Res Clin Pract 17:43–50CrossRefPubMed Rosenfalck AM, Bendtson I, Jorgensen S, Binder C (1992) Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin-dependent) diabetic patients. Diabetes Res Clin Pract 17:43–50CrossRefPubMed
45.
Zurück zum Zitat Wolfe T, Barton E (2003) Nasal drug delivery in EMS: reducing needlestick risk. JEMS 28:52–63PubMed Wolfe T, Barton E (2003) Nasal drug delivery in EMS: reducing needlestick risk. JEMS 28:52–63PubMed
46.
Zurück zum Zitat Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24CrossRefPubMed Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC (2007) Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 337:1–24CrossRefPubMed
47.
Zurück zum Zitat Hall-Boyer K, Zaloga GP, Chernow B (1984) Glucagon: hormone or therapeutic agent? Crit Care Med 12:584–589CrossRefPubMed Hall-Boyer K, Zaloga GP, Chernow B (1984) Glucagon: hormone or therapeutic agent? Crit Care Med 12:584–589CrossRefPubMed
48.
Zurück zum Zitat Lee H, Hosein EA (1982) Chronic alcohol feeding and its withdrawal on the structure and function of the rat liver plasma membrane: a study with 125I-labelled glucagon binding as a metabolic probe. Can J Physiol Pharmacol 60:1171–1176CrossRefPubMed Lee H, Hosein EA (1982) Chronic alcohol feeding and its withdrawal on the structure and function of the rat liver plasma membrane: a study with 125I-labelled glucagon binding as a metabolic probe. Can J Physiol Pharmacol 60:1171–1176CrossRefPubMed
49.
Zurück zum Zitat American Medical Association, Council on Drugs (1994) AMA Drug Evaluations Annual 1994. American Medical Association, Chicago, IL, p 1045 American Medical Association, Council on Drugs (1994) AMA Drug Evaluations Annual 1994. American Medical Association, Chicago, IL, p 1045
50.
Zurück zum Zitat MacCuish AC, Munro JF, Duncan LJ (1970) Treatment of hypoglycaemic coma with glucagon, intravenous dextrose, and mannitol infusion in a hundred diabetics. Lancet 2:946–949CrossRefPubMed MacCuish AC, Munro JF, Duncan LJ (1970) Treatment of hypoglycaemic coma with glucagon, intravenous dextrose, and mannitol infusion in a hundred diabetics. Lancet 2:946–949CrossRefPubMed
51.
Zurück zum Zitat Muhlhauser I, Berger M, Sonnenberg G, Koch J, Jorgens V, Schernthaner G, Scholz V, Padagogin D (1985) Incidence and management of severe hypoglycemia in 434 adults with insulin-dependent diabetes mellitus. Diabetes Care 8:268–273CrossRefPubMed Muhlhauser I, Berger M, Sonnenberg G, Koch J, Jorgens V, Schernthaner G, Scholz V, Padagogin D (1985) Incidence and management of severe hypoglycemia in 434 adults with insulin-dependent diabetes mellitus. Diabetes Care 8:268–273CrossRefPubMed
52.
Zurück zum Zitat Slama G, Reach G, Cahane M, Quetin C, Villanove-Robin F (1992) Intranasal glucagon in the treatment of hypoglycaemic attacks in children: experience at a summer camp. Diabetologia 35:398CrossRefPubMed Slama G, Reach G, Cahane M, Quetin C, Villanove-Robin F (1992) Intranasal glucagon in the treatment of hypoglycaemic attacks in children: experience at a summer camp. Diabetologia 35:398CrossRefPubMed
53.
Zurück zum Zitat Castle JR, Engle JM, El Youssef J, Massoud RG, Ward WK (2010) Factors influencing the effectiveness of glucagon for preventing hypoglycemia. J Diabetes Sci Technol 4:1305–1310CrossRefPubMedCentralPubMed Castle JR, Engle JM, El Youssef J, Massoud RG, Ward WK (2010) Factors influencing the effectiveness of glucagon for preventing hypoglycemia. J Diabetes Sci Technol 4:1305–1310CrossRefPubMedCentralPubMed
57.
Zurück zum Zitat Carstens S, Sprehn M (1998) Prehospital treatment of severe hypoglycaemia: a comparison of intramuscular glucagon and intravenous glucose. Prehosp Disaster Med 13:44–50PubMed Carstens S, Sprehn M (1998) Prehospital treatment of severe hypoglycaemia: a comparison of intramuscular glucagon and intravenous glucose. Prehosp Disaster Med 13:44–50PubMed
59.
Zurück zum Zitat Collier A, Steedman DJ, Patrick AW, Nimmo GR, Matthews DM, MacIntyre CC, Little K, Clarke BF (1987) Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department. Diabetes Care 10:712–715CrossRefPubMed Collier A, Steedman DJ, Patrick AW, Nimmo GR, Matthews DM, MacIntyre CC, Little K, Clarke BF (1987) Comparison of intravenous glucagon and dextrose in treatment of severe hypoglycemia in an accident and emergency department. Diabetes Care 10:712–715CrossRefPubMed
60.
Zurück zum Zitat Patrick AW, Collier A, Hepburn DA, Steedman DJ, Clarke BF, Robertson C (1990) Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycaemic coma in an accident and emergency department. Arch Emerg Med 7:73–77CrossRefPubMedCentralPubMed Patrick AW, Collier A, Hepburn DA, Steedman DJ, Clarke BF, Robertson C (1990) Comparison of intramuscular glucagon and intravenous dextrose in the treatment of hypoglycaemic coma in an accident and emergency department. Arch Emerg Med 7:73–77CrossRefPubMedCentralPubMed
61.
Zurück zum Zitat Stenninger E, Aman J (1993) Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:931–935CrossRefPubMed Stenninger E, Aman J (1993) Intranasal glucagon treatment relieves hypoglycaemia in children with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 36:931–935CrossRefPubMed
62.
Zurück zum Zitat Slama G, Alamowitch C, Desplanque N, Letanoux M, Zirinis P (1990) A new non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon. Diabetologia 33:671–674CrossRefPubMed Slama G, Alamowitch C, Desplanque N, Letanoux M, Zirinis P (1990) A new non-invasive method for treating insulin-reaction: intranasal lyophylized glucagon. Diabetologia 33:671–674CrossRefPubMed
63.
Zurück zum Zitat El Youssef J, Castle JR, Bakhtiani PA, Haidar A, Branigan DL, Breen M, Ward WK (2014) Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care. doi:10.2337/dc14-0803 El Youssef J, Castle JR, Bakhtiani PA, Haidar A, Branigan DL, Breen M, Ward WK (2014) Quantification of the glycemic response to microdoses of subcutaneous glucagon at varying insulin levels. Diabetes Care. doi:10.​2337/​dc14-0803
64.
Zurück zum Zitat Rudders SA, Banerji A, Corel B, Clark S, Camargo CA Jr (2010) Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics 125:e711–e718CrossRefPubMedCentralPubMed Rudders SA, Banerji A, Corel B, Clark S, Camargo CA Jr (2010) Multicenter study of repeat epinephrine treatments for food-related anaphylaxis. Pediatrics 125:e711–e718CrossRefPubMedCentralPubMed
Metadaten
Titel
Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations
verfasst von
Augusto Boido
Valerio Ceriani
Antonio E. Pontiroli
Publikationsdatum
01.04.2015
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 2/2015
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0665-0

Weitere Artikel der Ausgabe 2/2015

Acta Diabetologica 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.